Biointaxis hosts a webinar on how to invest in its gene therapy FRATAXAV® for Friedreich’s ataxia

by Capital Cell

Biointaxis, an academic spin-off from the Germans Trias i Pujol Research Institute (IGTP) founded in 2018, is developing the first drug designed to prevent and reverse the neurological and cardiac eff...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Regenera Levante partners with Magnum Ca...

by Magnum Capital Partners

Over little more than a decade, Regenera has built a strong track reco...

Photos Stream